Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
antineoplastic agent |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:brand |
gptkb:Padcev
|
| gptkbp:CASNumber |
2028263-64-7
|
| gptkbp:contains |
gptkb:monoclonal_antibody
MMAE |
| gptkbp:developer |
gptkb:Seagen
gptkb:Astellas_Pharma |
| https://www.w3.org/2000/01/rdf-schema#label |
enfortumab vedotin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
delivers cytotoxic agent to nectin-4 expressing cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
fatigue alopecia peripheral neuropathy rash hyperglycemia |
| gptkbp:target |
nectin-4
|
| gptkbp:usedFor |
gptkb:urothelial_carcinoma
bladder cancer |
| gptkbp:bfsParent |
gptkb:Padcev
|
| gptkbp:bfsLayer |
6
|